Minuteman Therapeutics develops oncolytic viruses engineered against an individual patient's tumour, matching the virus to the biology of that person's cancer.
Oncolytic viruses infect and kill cancer cells and alert the immune system to them; talimogene laherparepvec is the approved example. Minuteman's stated approach is personalised: an oncolytic virus designed against the individual patient's tumour rather than one product for all. It is an Even One Ventures portfolio company with no published trials.
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
Shares Even One Ventures and the tags startup, evenone-portfolio.